Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules for rare diseases, has scheduled its third quarter 2024 financial results release for Wednesday, November 13, 2024, before U.S. market open. The company will host a conference call and webcast at 8:00 a.m. ET to discuss results and provide corporate updates. Participants can register online to receive dial-in details and a unique PIN. The webcast will be available through the company's Investor Relations section, with an archived replay accessible afterward.
Fulcrum Therapeutics (Nasdaq: FULC), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di piccole molecole per malattie rare, ha programmato il rilascio dei risultati finanziari del terzo trimestre 2024 per mercoledì 13 novembre 2024, prima dell'apertura del mercato statunitense. L'azienda ospiterà una teleconferenza e una trasmissione web alle 8:00 ET per discutere i risultati e fornire aggiornamenti aziendali. I partecipanti possono registrarsi online per ricevere i dettagli per il collegamento e un PIN unico. La trasmissione web sarà disponibile nella sezione Relazioni con gli Investitori dell'azienda, con una replica archiviata accessibile in seguito.
Fulcrum Therapeutics (Nasdaq: FULC), una compañía biofarmacéutica en etapa clínica centrada en el desarrollo de moléculas pequeñas para enfermedades raras, ha programado la publicación de sus resultados financieros del tercer trimestre de 2024 para el miércoles 13 de noviembre de 2024, antes de la apertura del mercado en EE. UU. La compañía llevará a cabo una llamada de conferencia y una transmisión web a las 8:00 a.m. ET para discutir los resultados y proporcionar actualizaciones corporativas. Los participantes pueden registrarse en línea para recibir detalles de acceso y un PIN único. La transmisión web estará disponible a través de la sección de Relaciones con los Inversores de la compañía, con una repetición archivada accesible posteriormente.
Fulcrum Therapeutics (Nasdaq: FULC)는 희귀 질환을 위한 소분자 개발에 중점을 둔 임상 단계의 바이오 제약 회사로, 2024년 3분기 재무 결과 발표를 2024년 11월 13일 수요일, 미국 시장 개장 전에 일정으로 잡았습니다. 회사는 동부 표준시 오전 8시에 결과를 논의하고 회사 업데이트를 제공하기 위해 컨퍼런스 콜과 웹캐스트를 주최할 예정입니다. 참가자는 온라인으로 등록하여 다이얼 인 세부정보와 고유 PIN을 받을 수 있습니다. 웹캐스트는 회사의 투자자 관계 섹션을 통해 제공되며, 이후 아카이브된 재생이 가능합니다.
Fulcrum Therapeutics (Nasdaq: FULC), une entreprise bio-pharmaceutique en phase clinique spécialisée dans le développement de petites molécules pour les maladies rares, a programmé la publication de ses résultats financiers du troisième trimestre 2024 pour le mercredi 13 novembre 2024, avant l'ouverture du marché américain. L'entreprise organisera une conférence téléphonique et un webinaire à 8h00 ET pour discuter des résultats et fournir des mises à jour. Les participants peuvent s'inscrire en ligne pour recevoir les détails de connexion et un code PIN unique. Le webinaire sera disponible dans la section Relations avec les investisseurs de l'entreprise, avec une rediffusion accessible par la suite.
Fulcrum Therapeutics (Nasdaq: FULC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung kleiner Moleküle zur Behandlung seltener Krankheiten konzentriert, hat die Veröffentlichung seiner Finanzergebnisse für das dritte Quartal 2024 auf Mittwoch, den 13. November 2024, vor der Eröffnung der US-Märkte terminiert. Das Unternehmen wird um 8:00 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu erörtern und Unternehmensupdates zu geben. Teilnehmer können sich online registrieren, um Zugangsdaten und eine eindeutige PIN zu erhalten. Der Webcast wird im Bereich Investor Relations der Firma verfügbar sein, mit einer späteren Archiv-Wiedergabe.
- None.
- None.
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2024 financial results will be released on Wednesday, November 13, 2024, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
When will Fulcrum Therapeutics (FULC) release Q3 2024 earnings?
What time is Fulcrum Therapeutics (FULC) Q3 2024 earnings call?
How can I access Fulcrum Therapeutics (FULC) Q3 2024 earnings call?
